| Nov 12 |
Compass Therapeutics GAAP EPS of -$0.08
|
| Nov 12 |
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
|
| Nov 8 |
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
| Nov 5 |
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M
|
| Oct 4 |
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
|
| Sep 3 |
Compass Therapeutics to Participate in Upcoming Investor Events
|
| Sep 2 |
Compass Therapeutics files $300M mixed securities shelf
|
| Aug 22 |
Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)
|
| Aug 12 |
Compass Therapeutics GAAP EPS of -$0.10, revenue of $0.85M
|
| Aug 12 |
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
|
